United States securities and exchange commission logo August 12, 2020 Robert J. Gould, Ph.D. President and Chief Executive Officer Fulcrum Therapeutics, Inc. 26 Landsdowne Street Cambridge, Massachusetts 02139 Re: Fulcrum Therapeutics, Inc. Registration Statement on Form S-3 Filed August 11, 2020 File No. 333-244136 Dear Dr. Gould: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Chris Edwards at (202) 551-6761 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Lia Der Marderosian, Esq.